Headlines

ST LOUIS, July 2, 2014 -- Lee Biosolutions Inc, a leading biotech company in the healthcare field serving the Global diagnostic industry is proud to announce that it will expand into a new 40,786 Sq.ft facility in the City of Maryland Heights end of 4th quarter 2014 . The need for a new space is in response to the companies rising growth into new markets and increased demand for its products.

The building was previously home to one of the KV Pharmaceuticals cutting edge facilities that dotted the surrounding business landscape in St. Louis County. The Increased analytical lab space is needed for Lee Bio's increased growth for bioanalytical research and development projects and its ever expanding bulk manufacturing requirements. The added capacity and resources will help the company achieve its projected growth through 2017.

Burton Lee, President and CEO says ,"With the rapid growth we have seen over the last few years, our current facility was not able to keep up with demand. The new building supports our strategic objective to further expand our product lines, increase our capacity on key contract manufacturing products requiring larger cGMP processing clean rooms and to create operational efficiencies to meet our clients requirements."

The company plans on doubling its payroll by 2016 and is currently seeking qualified candidates to fill several positions by first quarter next year. The company has set up a career page to easily fill out and send in your resume.

Lee Biosolutions success in the aquisition of this outstanding new facility was achieved by having a great team which included Dan Dokovic from Intelica CRE, Kelly Shamel from Greensfelder Hemker & Gale, P.C, Jack Mannebach and Stephen Kuhn of Heartland Bank, Steve Grelle from the St. Louis Economic Development Partnership and The City Of Maryland Heights.

Lee Biosolutions is a key manufacturer of high purity enzymes and related proteins that include tumor markers, cardiac markerS, specialty diagnostic proteins for immunological diseases and biomarkers. The company is known internationally for developing some of the most successful formulations for research, diagnostic and therapeutic markets.

You can learn more about the company, its products, services and career opportunities by visiting its website at www.leebio.com

Lee Biosolutions, is a manufacturer and producer of high purity proteins announces a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, they are producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.

According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increases by 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee Biosolutions proteins Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.

"Gastric cancer screening involves H Pylori infection detection, measurement of serum pepsinogen I and II levels and possibly endoscopic examination.  ," said Burton Lee, president of Lee Biosolutions. "The challenge to-date for diagnostic companies  has been producing  tests efficiently and affordably. Recently, Lee Biosolutions research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomarkers to make a significant impact."

Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. Lee currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and immunoreagents. Headquartered in St. Louis and founded in 1975, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee Biosolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit www.LeeBio.com .

Lee Biosolutions Inc, a U.S. manufacturer, producer and supplier of high purity proteins and antigens announces the isolation and increased production of Serum Tumor Markers for the management of testicular germ cell tumors. The St. Louis-based healthcare- biotechnology firm has developed a unique proprietary process to effectively and efficiently purify beta Human Chorionic Gonadotropin, Alpha fetoprotein and Lactate dehydrogenase. As a result, Lee is now is a preferred producer for researchers and diagnostic companies to supply these critical components that are used in early detection of testicular cancer.

According to the American Cancer Society, there will be almost 9000 new cases of testicular cancer diagnosed in the United States this year. Although the rate of testicular cancer is rising for unknown reasons worldwide the death rate is low because of early detection and advances in the treatment of testicular cancer. Testicular cancer can develop in one or both testicles with over 90 percent of cancers in the testicle develop in special cells known as germ cells. Germ cells Scientists have found few risk factors that make a man more likely to develop testicular cancer.

Lee’s testicular germ cell tumor marker production capabilities enables in vitro diagnostics companies to manufacture diagnostic tests , which are affordable and easy to administer. Lee has scaled up production to meet global market demand. Beta Human Chorionic Gonadotropin (Beta HCG), alpha fetoprotein (AFP ) and Lactate Dehydrogenase (LDH) produced by Lee Biosolutions are used in the management of testicular germ cell tumors.

“Lee Biosolutions is on the forefront of Testicular Cancer research by supplying highly purified markers such as beta HCG, alpha fetoprotein and lactate dehydrogenase. Most testicular cancers are found by men themselves. If a lump is detected the doctor would recommend blood tests to determine levels of tumor markers to determine the proper diagnosis. Testicular cancer is survivable if treated early enough by the removal of the testicle. Its when you ignore the signs and you find yourself with Stage III cancer that has spread to the lungs, liver, bones and brain that survival rates diminish,” said Burton Lee, President of Lee Biosolutions.

Lee BioSolutions is an international producer and supplier of high purity finished proteins. Headquartered in St. Louis and founded in 2002, the healthcare biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes raw biomaterials used in drug discovery and development, diagnostic controls and calibrators, clinical diagnosis and product testing. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. For more information go to Lee Biosolutions website at leebio.com

Lee Biosolutions Manufactures   Myeloperoxidase  and CRP, Key Prognostic Markers of Inflammation of  Cardiovascular Disease

ST. LOUIS , MO  Lee Biosolutions Inc, an international manufacturer, producer and supplier of high purity proteins and antigens announces the isolation and increased production of Myeloperoxidase isolated from Leukocytes and C-Reactive Protein from Pleural Fluid.   The St. Louis-based  biotechnology firm has  developed a unique  proprietary process to effectively and efficiently purify  the  Myeloperoxidase and C-Reactive Protein  used in the prediction of Cardiovascular Disease. As a result, Lee is now is a preferred producer for researchers and  diagnostic companies to supply these critical components .

According to the Centers of Disease and Control, over 40% of all deaths in the United States are attributed to Cardiovascular Disease which means over 1 million of us die every year.  Several risk factors are used by doctors to determine the risk of developing CVC and what better way to access an individual than to test and predict that they will have cardiovascular disease.

LeeBio's new  Myeloperoxidase and C-Reactive Protein production capabilities enables international diagnostics companies  to quickly manufacture diagnostic tests , which are affordable and easy to administer. Lee has scaled up production to meet global market demand.

“Lee Biosolutions is on the forefront of Cardiovascular  research  by supplying  highly purified  markers such as C-Reactive Protein and  Myeloperoxidase .  “ said Burton Lee, President of Lee Biosolutions  . “  You will find the future of clinical diagnostics will utilize a greater number of  combination of biomarkers to predict early clinical diagnosis of diseases as they are identified.”

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer and supplier of high purity finished  human proteins.  Headquartered in St. Louis and founded in 2002, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include Low Denisity Lipoprotein (LDL),High Denisity Lipoprotein (HDL), CkMB and Troponin,  The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit www.LeeBio.com or call 314-968-1091.

Lee Biosolutions Inc, a U.S. manufacture of high purity finished proteins has increased production capacity for important enzymes used in liver function blood tests worldwide. The St. Louis-based healthcare- biotechnology firm has been able to keep up with demand for aminotransferase enzymes by increasing yields through newly developed purification methodologies.

The liver is not only the largest organ but the largest gland in the human body which plays an important role by filtering and processing blood as it circulates through the body. The functions of the liver include detoxification of your blood, production of important clotting factors and other proteins, processing nutrients, waste products of hemoglobin and storing vitamins, cholesterol and bile while also producing glucose. The cells in the liver contain proteins called enzymes that drive these chemical reactions. When the liver cells are damaged or destroyed, the enzymes in the cells leak out to the blood where they can be measured by blood tests. The liver function tests include measuring two main enzymes, Aspartate Aminotransferase called AST (GOT) and Alanine Aminotransferase ALT (SGPT) which when elevated is a strong sign of liver damage or disease.

According to Burton Lee, President of Lee Biosolutions, “The enzymes that are produced for liver function tests are actually isolated from porcine and bovine sources at our facility in St. Louis. Our production chemists process literally thousands of kgs of high quality tissue from USDA slaughter houses at a time in order to isolate and purify just a few hundred grams of a single enzyme. Careful monitoring of critical points in the process is needed to insure a stable high quality product. Our finished enzymes are then purchased under strict specifications by major IVD companies such as Bio-Rad Laboratories who produce the reagents and blood tests for hospitals to aid in the diagnoses if someone has alcoholic liver disease, viral hepatitis, and acute or chronic liver injury. Its very satisfying to know the products that you produce are helping save lives."

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer high purity finished proteins. Headquartered in St. Louis and founded in 2002, the healthcare biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes proteins and antibodies used in drug discovery and development, clinical diagnostic and immunodiagnostic market. The company is ISO 9001:2008 certified, has an active fan base on facebook ,is FDA and APHIS certified. To learn more about Lee BioSolutions visit http://www.LeeBio.com.